NEW YORK (GenomeWeb) – Biodesix said today that it has received a positive coverage decision from Highmark, a Blue Cross Blue Shield affiliate, for its Veristrat lung cancer test.

With the decision, Veristrat, which is intended to help guide second-line treatment in patients with advanced non-small cell lung cancer, gains access to Highmark's membership of 5.3 million people, the fourth-largest membership among BCBS-affiliated companies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

In Nature this week: a Danish reference genome, and more.